McKesson stock analysis
McKesson (MCK) Stock Price & Analysis
MCK Stock Chart & Stats
- Day’s Range
- EUR 944.80 - EUR 967.40
- 52-Week Range
- EUR 611.60 - EUR 973.60
- Previous Close
- EUR 973.60
- Volume
- N/A
- Average Volume (3M)
- 12
- Market Cap
- EUR 109.14B
- Enterprise Value
- EUR 107.12B
- Total Cash (Recent Filing)
- EUR 6.53B
- Total Debt (Recent Filing)
- EUR 11.16B
- Price to Earnings (P/E)
- 27.1
- Beta
- 0.04
- Next Earnings
- Feb 10, 2027 (Est.)
- EPS Estimate
- 9.72
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- 0.31%
Bulls Say, Bears Say
Bulls Say
Cash Generation
Strong cash conversion gives McKesson internal funding for technology, operations, acquisitions, debt service, and shareholder returns. Free cash flow near net income also supports earnings quality, making the business more resilient despite its low-margin distribution model.
Broad-based Growth
Growth across all four operating segments indicates that performance is not dependent on a single product or customer category. Broad revenue and earnings expansion can strengthen operating leverage and support continued investment over the next several quarters.
Specialty-care Expansion
The Precision Medicine Group acquisition expands McKesson’s position in oncology, rare diseases, cell and gene therapies, and commercialization services. These capabilities can deepen customer relationships and diversify growth toward complex, higher-value healthcare services.
Bears Say
Leverage And Negative Equity
Negative equity and rising debt leave McKesson with a limited equity cushion and less financial flexibility if profitability weakens. Leverage also increases sensitivity to interest costs and operating setbacks, potentially constraining future investment and capital allocation.
Thin Margins
Very low distribution margins leave limited room for pricing, cost, or execution errors. Even modest pressure on purchasing economics, reimbursement, or operating efficiency could materially affect earnings, while declining margins suggest that profitability remains structurally sensitive.
MedSurg Weakness
The medical-surgical segment is producing a persistent earnings drag: management expects revenue growth but little to no operating-profit improvement. Continued margin pressure in this business could dilute stronger results elsewhere and reduce the benefit of consolidated growth.
MCK FAQ
What was McKesson’s price range in the past 12 months?
What is McKesson’s market cap?
When is McKesson’s upcoming earnings report date?
How were McKesson’s earnings last quarter?
Is McKesson overvalued?
Does McKesson pay dividends?
What is McKesson’s EPS estimate?
How many shares outstanding does McKesson have?
What happened to McKesson’s price movement after its last earnings report?
Which hedge fund is a major shareholder of McKesson?
What is the TipRanks Smart Score and how is it calculated?
McKesson Stock Smart Score
Company Description
McKesson
McKesson Corporation is a prominent global provider of healthcare services, operating extensively in both the United States and international markets. Its diverse operations are strategically organized into four key business segments. The U.S. Pharmaceutical division plays a crucial role in the distribution of a comprehensive array of pharmaceutical products, encompassing branded, generic, specialty, biosimilar, and over-the-counter medications, alongside other health-related merchandise. This segment also delivers specialized support to community-based oncology and other specialty medical practices through practice management tools, technology solutions, clinical guidance, and broader business services. Furthermore, it assists pharmacies with consulting, outsourcing, and technology services, while also furnishing financial, operational, and clinical software solutions. Internationally, the company's dedicated segment provides distribution and support services to wholesale, institutional, and retail clients across 13 European nations and Canada. The Medical-Surgical Solutions unit is focused on supplying healthcare providers with essential medical-surgical products, sophisticated logistics management, and a variety of associated services. Finally, the Prescription Technology Solutions (RxTS) segment is designed to address complex medication challenges for patients. It collaborates with biopharmaceutical companies and life sciences partners to improve patient journeys, leveraging innovative solutions for medication access and adherence by connecting pharmacies, healthcare providers, payers, and biopharma entities. This segment further offers third-party logistics and wholesale distribution assistance. Founded in 1833, McKesson Corporation maintains its corporate headquarters in Irving, Texas.
- Sector
- Healthcare
- Industry
- Medical - Distribution
- CEO
- Brian S. Tyler
- Employees
- 42,300
- Website
- www.mckesson.com
- Address
- 6555 State Highway 161, Irving, TX, 75039, US
McKesson (MCK) Earnings & Revenues
MCK Company Deck
MCK Earnings Call
Earnings Call SentimentPositive
The call was strongly positive. McKesson reported broad-based revenue, operating profit, and adjusted EPS growth; raised fiscal 2027 guidance; highlighted strong cash generation, liquidity, shareholder returns, and strategic expansion in oncology, biopharma services, specialty care, and home-based infusion. The principal challenges were the medical-surgical operating profit decline and muted outlook, branded pharmaceutical pricing and generic conversions, higher interest expense, normalized prior authorization volumes, and uncertainty around 340B policy. These lowlights were outweighed by the company's reported performance, raised outlook, and strategic momentum.
View all DE:MCK earnings summariesMCK Net sales Breakdown
- 83.45% North American Pharmaceutical
- 12.00% Oncology & Multispecialty
- 1.44% Prescription Technology Solutions
- 2.85% Medical-Surgical Solutions
- 0.26% Other
MCK Stock 12 Month Forecast
Average Price Target
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 16 | 2 | 4 |
| Technical Analysis | 4 | 2 | 4 |
| Moving Averages | 12 | 0 | 0 |
